1887
  1. Home
  2. Eurosurveillance
  3. Volume 22, Issue 7, 16/Feb/2017
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0–14, 15–64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65–79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2017.22.7.30464
2017-02-16
2024-11-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2017.22.7.30464
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/22/7/eurosurv-22-30464-1.html?itemId=/content/10.2807/1560-7917.ES.2017.22.7.30464&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Risk assessment of seasonal influenza, EU/EEA, 2016-2017 - Update 25 January 2017 Stockholm: ECDC; 2017. Available from: http://ecdc.europa.eu/en/publications/Publications/Risk-assessment-seasonal-influenza-2016-2017-update.pdf
  2. European monitoring of excess mortality for public health action (EuroMOMO). Mortality monitoring in Europe mortality bulletin, week 1-2017. Copenhagen: EuroMOMO. [Accessed 20 Jan 2017]. Available from: http://www.euromomo.eu/
  3. Säsongstatistik för influensa 2016/2017 [Season statistics for influenza 2016/2017]. Stockholm: Smittskydd Stockholm. [Accessed: 4 Feb 2017]. Swedish. Available from: http://www.vardgivarguiden.se/behandlingsstod/smittskydd/dokument/statistik/influensa/sasongen-2016-2017/
  4. Ajantasainen influenssakatsaus. [Real-time influenza report]. Helsinki: National Institute for Health and Welfare (THL). [Accessed: 14 Feb 2017]. Finnish. Available from: https://www.thl.fi/fi/web/infektiotaudit/taudit-ja-mikrobit/virustaudit/influenssa/ajantasainen-influenssakatsaus
  5. Rondy M, Launay O, Puig-Barberà J, Gefenaite G, Castilla J, de Gaetano Donati K, et al. European hospital IVE network. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. Euro Surveill. 2015;20(2):21011.  https://doi.org/10.2807/1560-7917.ES2015.20.2.21011  PMID: 25613779 
  6. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill. 2014;19(6):20701.  https://doi.org/10.2807/1560-7917.ES2014.19.6.20701  PMID: 24556348 
  7. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, et al. Joan O´DonellI-MOVE multicentre case-control team. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill. 2016;21(7):30139.  https://doi.org/10.2807/1560-7917.ES.2016.21.7.30139  PMID: 26924024 
  8. European Centre for Disease Prevention and Control (ECDC). Protocol for case control studies to measure pandemic and seasonal vaccine effectiveness in the European Union and European Economic Area. Stockholm: ECDC; 2009. Available from: http://ecdc.europa.eu/en/publications/Publications/0907_TED_Influenza_AH1N1_Measuring_Influenza_Vaccine_Effectiveness_Protocol_Case_Control_Studies.pdf
  9. EpiConcept. Protocol for hospital-based test negative case control studies to measure seasonal influenza vaccine effectiveness against influenza laboratory confirmed SARI hospitalisation among the elderly across the European Union and European Economic Area Member States. Paris: I-MOVE+. [Accessed: 5 Feb 2017]. Available from: https://drive.google.com/a/epiconcept.fr/file/d/0B54XpZN4SY65QXFqQThQNEQ5cmM/view
  10. Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter A, De Serres G, et al. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. Euro Surveill. 2017;22(6):30460.  https://doi.org/10.2807/1560-7917.ES.2017.22.6.30460 
  11. Kissling E, Valenciano MI-MOVE Case-Control Studies Team. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case-control study, 2011/12. Euro Surveill. 2012;17(15):20146. PMID: 22516046 
  12. Valenciano M, Kissling EI-MOVE Case-Control Study Team. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13. Euro Surveill. 2013;18(7):3. PMID: 23449183 
  13. World Health Organization (WHO). WHO consultation and information meeting on the composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. Geneva: WHO. [Accessed: 5 Feb 2017]. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/consultation201702/en/
  14. Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al. I-MOVE case–control study team. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill. 2016;21(16):30201.  https://doi.org/10.2807/1560-7917.ES.2016.21.16.30201  PMID: 27124420 
  15. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942-51.  https://doi.org/10.1016/S1473-3099(16)00129-8  PMID: 27061888 
Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Esther+Kissling&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kissling Esther</a>, <a href="/search?value1=Marc+Rondy&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rondy Marc</a>, <a href="/search?value1=I-MOVE%2FI-MOVE%2B+study+team&option1=author&noRedirect=true" class="nonDisambigAuthorLink">I-MOVE/I-MOVE+ study team</a></span>. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. <a href="/content/ecdc">Euro Surveill.</a> 2017;22(7):pii=30464. <a href="https://doi.org/10.2807/1560-7917.ES.2017.22.7.30464" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2017.22.7.30464</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 09 Feb 2017;&nbsp;&nbsp; <span class="generated">Accepted</span>: 16 Feb 2017 </span> </p>
/content/10.2807/1560-7917.ES.2017.22.7.30464
/content/10.2807/1560-7917.ES.2017.22.7.30464
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error